A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple sclerosis portfolio. Management attributed much of the growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which together posted significant year-on-year gains. CEO Christopher Viehbacher highlighted that “launch products again in this quarter, and if I look at this year-to-date as well, more than have offset the MS decline on a year-to-date basis.” Despite generic pressures in Europe, particularly for the MS franchise, the company’s ability to grow new products and maintain cost discipline supported an improved operating margin.
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.
Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced Research Projects Agency (DARPA), as the inaugural director of the Advanced Research Projects Agency for Health (ARPA-H). Announced by President Joe Biden with her official appointment on [...]
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 8.6% has lagged the S&P 500’s 22.9% climb.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ:AMD) surging nearly 30% after unveiling a landmark investment in OpenAI.
